Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002033844 | SCV002286891 | uncertain significance | Muscle AMP deaminase deficiency | 2023-12-21 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 263 of the AMPD1 protein (p.Lys263Glu). This variant is present in population databases (rs138705920, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with AMPD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1498037). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002642051 | SCV003681613 | uncertain significance | Inborn genetic diseases | 2021-07-21 | criteria provided, single submitter | clinical testing | The c.787A>G (p.K263E) alteration is located in exon 6 (coding exon 6) of the AMPD1 gene. This alteration results from a A to G substitution at nucleotide position 787, causing the lysine (K) at amino acid position 263 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV002033844 | SCV003826267 | uncertain significance | Muscle AMP deaminase deficiency | 2020-01-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004691485 | SCV005186835 | uncertain significance | not provided | criteria provided, single submitter | not provided |